mhurhangee/patent-ind-claim-en huggingface dataset:
A compound of formula (I): wherein: - R 1 represents a halogen atom or hydrogen atom; - R 2 represents a six-membered heteroaryl ring containing carbon, hydrogen and one or more nitrogen atoms, optionally substituted by one or more substituents selected from the group consisting of halogen atom, C 1 -C 4 haloalkyl, linear or branched C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, linear or branched C 1 -C 6 alkoxy and C 3 -C 12 cycloalkoxy groups; - R 3 represents a six-membered heteroaryl ring containing carbon, hydrogen and one or more nitrogen atoms, optionally substituted by one or more substituents selected from the group consisting of halogen atom, C 1 -C 4 haloalkyl, linear or branched C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, linear or branched C 1 -C 6 alkoxy and C 3 -C 12 cycloalkoxy groups; N-oxide of said compounds and pharmaceutically acceptable salt thereof, with the proviso that compound of formula (I) is not: - 5-(pyridin-4-yl)-6-(pyridin-4-yl)pyridin-2-amine - 5-(pyridin-3-yl)-6-(pyridin-3-yl)pyridin-2-amine - 5-(pyrazin-2-yl)-6-(pyridin-4-yl)pyridin-2-amine - 5-(4-methylpyridin-2-yl)-6-(pyridin-4-yl)pyridin-2-amine - R 1 represents a halogen atom or hydrogen atom; - R 2 represents a six-membered heteroaryl ring containing carbon, hydrogen and one or more nitrogen atoms, optionally substituted by one or more substituents selected from the group consisting of halogen atom, C 1 -C 4 haloalkyl, linear or branched C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, linear or branched C 1 -C 6 alkoxy and C 3 -C 12 cycloalkoxy groups; - R 3 represents a six-membered heteroaryl ring containing carbon, hydrogen and one or more nitrogen atoms, optionally substituted by one or more substituents selected from the group consisting of halogen atom, C 1 -C 4 haloalkyl, linear or branched C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, linear or branched C 1 -C 6 alkoxy and C 3 -C 12 cycloalkoxy groups; - 5-(pyridin-4-yl)-6-(pyridin-4-yl)pyridin-2-amine - 5-(pyridin-3-yl)-6-(pyridin-3-yl)pyridin-2-amine - 5-(pyrazin-2-yl)-6-(pyridin-4-yl)pyridin-2-amine - 5-(4-methylpyridin-2-yl)-6-(pyridin-4-yl)pyridin-2-amine
A communications method performed by a terminal device, the method comprising the steps of: receiving a cell global identifier, CGI, request message with respect to a target cell from a network device; and determining , based on a capability of the terminal device, whether to report a CGI of the target cell to the network device, wherein the capability is related to a type of a first-type network, and the target cell belongs to the first-type network; wherein the first-type network comprises any one of the following networks: a public land mobile network, a standalone non-public network, a non-standalone non-public network, and a non-terrestrial network. receiving a cell global identifier, CGI, request message with respect to a target cell from a network device; and determining , based on a capability of the terminal device, whether to report a CGI of the target cell to the network device, wherein the capability is related to a type of a first-type network, and the target cell belongs to the first-type network; wherein the first-type network comprises any one of the following networks: a public land mobile network, a standalone non-public network, a non-standalone non-public network, and a non-terrestrial network.
A method for wireless communication, comprising: identifying a pilot signal and a payload to be transmitted in a first full symbol, the first full symbol including a first symbol cyclic prefix; formatting the pilot signal and the payload in the time domain into separate sub-symbols that are nested within the first full symbol with each sub-symbol including an associated sub-symbol cyclic prefix, wherein the formatting comprises: identifying a first cyclic prefix length for the first symbol cyclic prefix; identifying a sub-symbol cyclic prefix length as the first cyclic prefix length divided by a number of the separate sub-symbols; formatting the pilot signal in front of the payload to be transmitted; identifying a tail portion of the pilot signal having the sub-symbol cyclic prefix length as a payload sub-symbol cyclic prefix; appending a copy of the payload sub-symbol cyclic prefix to an end of the payload in the payload sub-symbol; identifying a payload sub-symbol tail portion having the first cyclic prefix length; and inserting a copy of the identified payload sub-symbol tail portion in front of the pilot signal sub-symbol; and transmitting the first full symbol, including the nested sub-symbols, to a receiver. identifying a pilot signal and a payload to be transmitted in a first full symbol, the first full symbol including a first symbol cyclic prefix; formatting the pilot signal and the payload in the time domain into separate sub-symbols that are nested within the first full symbol with each sub-symbol including an associated sub-symbol cyclic prefix, wherein the formatting comprises: identifying a first cyclic prefix length for the first symbol cyclic prefix; identifying a sub-symbol cyclic prefix length as the first cyclic prefix length divided by a number of the separate sub-symbols; formatting the pilot signal in front of the payload to be transmitted; identifying a tail portion of the pilot signal having the sub-symbol cyclic prefix length as a payload sub-symbol cyclic prefix; appending a copy of the payload sub-symbol cyclic prefix to an end of the payload in the payload sub-symbol; identifying a payload sub-symbol tail portion having the first cyclic prefix length; and inserting a copy of the identified payload sub-symbol tail portion in front of the pilot signal sub-symbol; and identifying a first cyclic prefix length for the first symbol cyclic prefix; identifying a sub-symbol cyclic prefix length as the first cyclic prefix length divided by a number of the separate sub-symbols; formatting the pilot signal in front of the payload to be transmitted; identifying a tail portion of the pilot signal having the sub-symbol cyclic prefix length as a payload sub-symbol cyclic prefix; appending a copy of the payload sub-symbol cyclic prefix to an end of the payload in the payload sub-symbol; identifying a payload sub-symbol tail portion having the first cyclic prefix length; and inserting a copy of the identified payload sub-symbol tail portion in front of the pilot signal sub-symbol; and transmitting the first full symbol, including the nested sub-symbols, to a receiver.
A method for producing a retinal cell or a retinal tissue, comprising the following steps - : a first step of culturing human pluripotent stem cells in the absence of feeder cells in a medium containing (i) a TGFβ family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and (ii) a factor for maintaining undifferentiated state, a second step of culturing the cells obtained in the first step in suspension in a medium containing a Wnt signal transduction pathway inhibiting substance to form a cell aggregate, and a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a Wnt signal transduction pathway inhibiting substance in a medium containing a BMP signal transduction pathway activating substance to obtain an aggregate containing a retinal cell or a retinal tissue wherein the TGFβ family signal transduction pathway inhibiting substance is selected from the group consisting of Lefty, SB431542, A-83-01, LDN193189 and Dorsomorphin, wherein the Sonic hedgehog signal transduction pathway activating substance is selected from the group consisting of Shh, SAG and Purmorphamine, wherein the Wnt signal transduction pathway inhibiting substance is selected from the group consisting of CKI-7, D4476, IWR-1-endo and IWP-2, and wherein the BMP signal transduction pathway activating substance is selected from the group consisting of BMP2, BMP4, BMP7 and GDF7. a first step of culturing human pluripotent stem cells in the absence of feeder cells in a medium containing (i) a TGFβ family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and (ii) a factor for maintaining undifferentiated state, a second step of culturing the cells obtained in the first step in suspension in a medium containing a Wnt signal transduction pathway inhibiting substance to form a cell aggregate, and a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a Wnt signal transduction pathway inhibiting substance in a medium containing a BMP signal transduction pathway activating substance to obtain an aggregate containing a retinal cell or a retinal tissue
Household refrigeration appliance with a housing , in which a first, upper receiving space for foodstuffs and a second, lower receiving space for foodstuffs that is separate therefrom are embodied, wherein the two receiving spaces are separated from one another on the front side by a crossbar of the household refrigeration appliance , and with a light module , which is arranged on a front side of the crossbar , wherein the light module has a module housing , characterised in that the module housing has a rear housing part , which has a rear wall and a plurality of separate snap-fit elements , wherein the snap-fit elements are embodied in one piece with the rear housing part and are snap-fitted into snap-fit element receptacles , which are embodied on the crossbar , wherein the rear housing part is in direct contact with a rear area of the rear wall in a planar manner on the front side , and that a circuit board of the light module is T-shaped, in particular a subregion of the circuit board is a T "stem", which extends through a slot in the rear wall of the rear housing part through the rear wall towards the rear and/or a further subregion of the circuit board is a T "roof, which is arranged in contact with a front area of the rear wall of the rear housing part .
A method of preparing a 2,6 disubstituted aniline, the method comprising: reacting a 2-amino isophthalic acid diester with sufficient Grignard reagent R 2 CH 2 MgX to form the corresponding diol product, wherein X is chloride, bromide or iodide, and R 2 is selected from H, methyl, ethyl, n-propyl and wherein either R 3 is H and R 4 is alkyl that may be substituted, or each of R 3 ,R 4 are an independently selected alkyl that may be substituted; dehydrating the diol product to the corresponding dialkene; and hydrogenating the dialkene product to form the corresponding aniline. reacting a 2-amino isophthalic acid diester with sufficient Grignard reagent R 2 CH 2 MgX to form the corresponding diol product, wherein X is chloride, bromide or iodide, and R 2 is selected from H, methyl, ethyl, n-propyl and wherein either R 3 is H and R 4 is alkyl that may be substituted, or each of R 3 ,R 4 are an independently selected alkyl that may be substituted; wherein either R 3 is H and R 4 is alkyl that may be substituted, or each of R 3 ,R 4 are an independently selected alkyl that may be substituted; dehydrating the diol product to the corresponding dialkene; and hydrogenating the dialkene product to form the corresponding aniline.
A deep pressure therapy blanket , comprising a piece of weighted material, the piece of weighted material comprising: a length of layered yarn that is interlooped to form the piece of weighted material, wherein the length of layered yarn comprises: an outer tube extending longitudinally from a first end to a second end, the outer tube defining a conduit extending longitudinally therethrough from the first end to the second end, the outer tube being formed of a rolled outer layer sheet ; and a plurality of inner layers of material disposed within the conduit and extending longitudinally from the first end to the second end, wherein the length of layered yarn , by itself, is configured and sufficiently weighted to effectuate deep pressure therapy to a person when the deep pressure therapy blanket lies over a person's body and wherein the piece of weighted material is configured to weigh between 2.27 kg and 20.41 kg (5 pounds and 45 pounds) inclusive. an outer tube extending longitudinally from a first end to a second end, the outer tube defining a conduit extending longitudinally therethrough from the first end to the second end, the outer tube being formed of a rolled outer layer sheet ; and a plurality of inner layers of material disposed within the conduit and extending longitudinally from the first end to the second end, wherein the length of layered yarn , by itself, is configured and sufficiently weighted to effectuate deep pressure therapy to a person when the deep pressure therapy blanket lies over a person's body and wherein the piece of weighted material is configured to weigh between 2.27 kg and 20.41 kg (5 pounds and 45 pounds) inclusive.
A process for the production of sponge iron from iron ore, the process comprising the steps: - charging (s303) iron ore into a direct reduction shaft ; - introducing (s305) a hydrogen-rich reducing gas comprising greater than 80 vol% hydrogen gas into the direct reduction shaft in order to reduce the iron ore and produce sponge iron ; - removing (s307) a top gas from the direct reduction shaft; - subjecting the top gas to heat exchange in order to cool the top gas and heat the hydrogen-rich reducing gas; - dividing (s309) the top gas into a recycle stream and a bleed-off stream ; - processing (s311) the bleed-off stream through a separation unit to provide a hydrogen-enriched off-stream and an inert-enriched off-stream ; and - introducing (s311) the recycle stream and the hydrogen-enriched off-stream as constituent parts of the hydrogen-rich reducing gas to the direct reduction shaft. - charging (s303) iron ore into a direct reduction shaft ; - introducing (s305) a hydrogen-rich reducing gas comprising greater than 80 vol% hydrogen gas into the direct reduction shaft in order to reduce the iron ore and produce sponge iron ; - removing (s307) a top gas from the direct reduction shaft; - subjecting the top gas to heat exchange in order to cool the top gas and heat the hydrogen-rich reducing gas; - dividing (s309) the top gas into a recycle stream and a bleed-off stream ; - processing (s311) the bleed-off stream through a separation unit to provide a hydrogen-enriched off-stream and an inert-enriched off-stream ; and - introducing (s311) the recycle stream and the hydrogen-enriched off-stream as constituent parts of the hydrogen-rich reducing gas to the direct reduction shaft.
A compound of Formula (I) wherein R 1 -R 3 each independently are alkyl, and at least one of R 1 -R 3 is disposed in the cis- position relative to the non-hydrogen substituent in the 1-position of the corresponding cyclohexanediyl moiety.
An inkjet ink comprising: (i) a disazo dye of formula (I): wherein: A is a C 6-14 aryl group having 0, 1, 2, 3, 4 or 5 substituents selected from the group consisting of: -SO 3 M, nitro, carboxyl, halogen, hydroxyl, amino, C 1-4 alkylamino, C 1-4 alkoxy, C 1-4 alkyl, C 1-4 haloalkyl, cyano, sulfonamide, carbamoyl, C 1-4 alkylamido and C 1-4 alkoxycarbonyl; B is a C 6-14 aryl group having 0, 1, 2, 3, 4 or 5 substituents selected from the group consisting of: -SO 3 M, nitro, carboxyl, halogen, hydroxyl, amino, C 1-4 alkylamino, C 1-4 alkoxy, C 1-4 alkyl, C 1-4 haloalkyl, cyano, sulfonamide, carbamoyl, C 1-4 alkylamido and C 1-4 alkoxycarbonyl; each M is independently selected from the group consisting of: hydrogen, lithium, sodium, potassium, ammonium and quaternary ammonium; and each of A and B has at least one substituent of formula -SO 3 M, such that the dye of formula (I) comprises at least 4 groups of formula -SO 3 M; (ii) 1,3-propanediol; (iii) a glycol compound selected from the group consisting of: triethylene glycol and tetraethylene glycol; and (iv) water. (i) a disazo dye of formula (I): wherein: A is a C 6-14 aryl group having 0, 1, 2, 3, 4 or 5 substituents selected from the group consisting of: -SO 3 M, nitro, carboxyl, halogen, hydroxyl, amino, C 1-4 alkylamino, C 1-4 alkoxy, C 1-4 alkyl, C 1-4 haloalkyl, cyano, sulfonamide, carbamoyl, C 1-4 alkylamido and C 1-4 alkoxycarbonyl; B is a C 6-14 aryl group having 0, 1, 2, 3, 4 or 5 substituents selected from the group consisting of: -SO 3 M, nitro, carboxyl, halogen, hydroxyl, amino, C 1-4 alkylamino, C 1-4 alkoxy, C 1-4 alkyl, C 1-4 haloalkyl, cyano, sulfonamide, carbamoyl, C 1-4 alkylamido and C 1-4 alkoxycarbonyl; each M is independently selected from the group consisting of: hydrogen, lithium, sodium, potassium, ammonium and quaternary ammonium; and each of A and B has at least one substituent of formula -SO 3 M, such that the dye of formula (I) comprises at least 4 groups of formula -SO 3 M; A is a C 6-14 aryl group having 0, 1, 2, 3, 4 or 5 substituents selected from the group consisting of: -SO 3 M, nitro, carboxyl, halogen, hydroxyl, amino, C 1-4 alkylamino, C 1-4 alkoxy, C 1-4 alkyl, C 1-4 haloalkyl, cyano, sulfonamide, carbamoyl, C 1-4 alkylamido and C 1-4 alkoxycarbonyl; B is a C 6-14 aryl group having 0, 1, 2, 3, 4 or 5 substituents selected from the group consisting of: -SO 3 M, nitro, carboxyl, halogen, hydroxyl, amino, C 1-4 alkylamino, C 1-4 alkoxy, C 1-4 alkyl, C 1-4 haloalkyl, cyano, sulfonamide, carbamoyl, C 1-4 alkylamido and C 1-4 alkoxycarbonyl; each M is independently selected from the group consisting of: hydrogen, lithium, sodium, potassium, ammonium and quaternary ammonium; and each of A and B has at least one substituent of formula -SO 3 M, such that the dye of formula (I) comprises at least 4 groups of formula -SO 3 M; (ii) 1,3-propanediol; (iii) a glycol compound selected from the group consisting of: triethylene glycol and tetraethylene glycol; and (iv) water.
A bacterial strain belonging to the species Lactobacillus paracasei identified as Lactobacillus paracasei LPC-S01 deposits to the Deutsche Sammlung van Mikroorganismen und Zellkulturen GmbH (DSMZ) with the access number DSM 26760 for use in a method of treatment, preventive and/or curative, of disorders and/or pathologies affecting the skin of an inflammatory type, or from exposure to UV radiations, - wherein said disorders and/or pathologies affecting the skin are selected from: dermatitis, dermatitis associated with irritations and excoriations, acne, skin infections, skin inflammations, erythema, ulcers, psoriasis, atopic dermatitis, rhagades, fistulas, hemorrhoids, and any other skin disorder or lesion with the presence of an ongoing inflammatory process. - wherein said disorders and/or pathologies affecting the skin are selected from: dermatitis, dermatitis associated with irritations and excoriations, acne, skin infections, skin inflammations, erythema, ulcers, psoriasis, atopic dermatitis, rhagades, fistulas, hemorrhoids, and any other skin disorder or lesion with the presence of an ongoing inflammatory process.
The medical device for inducing a controlled fluid transport in a central nervous system, CNS, and/or in a cerebrospinal fluid, CSF, system of a patient by electro-osmosis, EO, via two or more electrodes placed at selected locations on the patients head, comprising: a computer program module, configured to receive EO information, the EO information being at least indicative of fluid transport response resulting from application of particular electric potentials and/or currents at particular electrode locations on the patient's head based on a patient-specific three-dimensional head model, and to receive a fluid source location within the patient's head, so as to select a set of electrode locations using the EO information and the fluid source location. a cap/helmet-like device , configured to place the two or more electrodes in electrical communication with said CNS/CSF-system, each electrode being placed at one location of the selected set of electrode locations, and a control unit , configured to control an application of selected electric potentials and/or electric currents to said electrodes, wherein the selected electric potentials and/or electric currents is selected as electric potentials and/or electric currents associated to the selected set of electrode locations by the EO information, so as to induce a controlled fluid transport in said CNS/CSF-system. a computer program module, configured to receive EO information, the EO information being at least indicative of fluid transport response resulting from application of particular electric potentials and/or currents at particular electrode locations on the patient's head based on a patient-specific three-dimensional head model, and to receive a fluid source location within the patient's head, so as to select a set of electrode locations using the EO information and the fluid source location. a cap/helmet-like device , configured to place the two or more electrodes in electrical communication with said CNS/CSF-system, each electrode being placed at one location of the selected set of electrode locations, and a control unit , configured to control an application of selected electric potentials and/or electric currents to said electrodes, wherein the selected electric potentials and/or electric currents is selected as electric potentials and/or electric currents associated to the selected set of electrode locations by the EO information, so as to induce a controlled fluid transport in said CNS/CSF-system.
Welding fixture for a bar truss girder, for holding pre-assembled elements to be welded by an automatic equipment to form said bar truss girder, characterised in that it comprises four supporting bars , joined at their opposed edges to two fixed plates , an intermediate moving plate , apt to longitudinally slide along said supporting bars , coupling means being provided on one of said fixed plates and on said moving plate for coupling with corresponding coupling means of carrying longitudinal elements of said bar truss girder to be welded, while second elements to be welded, constituted by the remaining elements to be welded to form said bar truss girder, being pre-assembled together with said longitudinal elements to be welded.